SCHEMBL20546353

SCHEMBL20546353

Cc1ccc(C(N)CC(=O)O)cc1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
FFAR1 O14842 5/20 0.44
SLC1A3 P43003 3/20 0.42
SLC1A2 P43004 3/20 0.42
SLC1A1 P43005 3/20 0.42
CTSA P10619 2/20 0.42
PTGS1 P23219 4/20 0.40
TPH1 P17752 1/20 0.40
MEN1 O00255 2/20 0.39
PTGS2 P35354 2/20 0.39
FABP2 P12104 1/20 0.39
TSHR P16473 1/20 0.39
AKR1C4 P17516 1/20 0.39
ADRA2B P18089 1/20 0.39
CHRM3 P20309 1/20 0.39
HTR2C P28335 1/20 0.39
DRD3 P35462 1/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20546351 1.00 KMT2A (0.47) KMT2ASMN1; SMN2FFAR1SLC1A3SLC1A2
SCHEMBL20546048 0.86 FFAR1 (0.50) KMT2ASMN1; SMN2FFAR1SLC1A3SLC1A2
SCHEMBL20546046 0.86 FFAR1 (0.50) KMT2ASMN1; SMN2FFAR1SLC1A3SLC1A2
SCHEMBL20545714 0.85 KMT2A (0.47) KMT2ASMN1; SMN2FFAR1SLC1A3SLC1A2
SCHEMBL20545289 0.85 SLC1A3 (0.54) KMT2ASMN1; SMN2FFAR1SLC1A3SLC1A2
SCHEMBL20545291 0.85 SLC1A3 (0.54) KMT2ASMN1; SMN2FFAR1SLC1A3SLC1A2
SCHEMBL20545715 0.85 KMT2A (0.47) KMT2ASMN1; SMN2FFAR1SLC1A3SLC1A2
SCHEMBL30541483 0.85 SMN1; SMN2 (0.43) KMT2ASMN1; SMN2SLC1A3SLC1A2SLC1A1
SCHEMBL28885092 0.85 SMN1; SMN2 (0.43) KMT2ASMN1; SMN2SLC1A3SLC1A2SLC1A1
SCHEMBL20546570 0.85 CTSA (0.47) KMT2ASMN1; SMN2SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615514-B1 PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF AVIARA PHARMACEUTICALS INC (US) 2023-11-22 EP disclosed
US-10875875-B2 Propionic acid derivatives and methods of use thereof AVIARA PHARMACEUTICALS, INC. (US) 2020-12-29 US disclosed
US-20180312523-A1 Propionic Acid Derivatives and Methods of Use Thereof AVIARA PHARMACEUTICALS, INC. (US) 2018-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180312523-A1 Propionic Acid Derivatives and Methods of Use Thereof ITGB3, ITGA1, ITGB5 KMT2A 4455/4885SMN1; SMN2 2021/4885FFAR1 37/4885
US-10875875-B2 Propionic acid derivatives and methods of use thereof ITGB3, ITGA1, ITGB5 KMT2A 4455/4885SMN1; SMN2 2021/4885FFAR1 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.